ArticleThoracic cancer2022

Survival benefits from afatinib compared with gefitinib and erlotinib among patients with common EGFR mutation in first-line setting.

Wang Chun Kwok et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.